New-Onset Complement-Mediated Thrombotic Microangiopathy during the COVID-19 Pandemic
Kidney and Blood Pressure Research · 2024
DOI: 10.1159/000541938 ↗Kurz gefasst
Fachartikel in der Zeitschrift Kidney and Blood Pressure Research, 2024. Verfasst von Christof Aigner und 9 weiteren Autor:innen. Beteiligte Einrichtung: Division of Nephrology and Dialysis, Department of Medicine III, Medical University of Vienna, Vienna, Austria. Hauptthemen laut MEDLINE: COVID-19, COVID-19 Vaccines, Thrombotic Microangiopathies. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Introduction
The coronavirus disease-19 (COVID-19) is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The virus is alleged to enable a proinflammatory state that leads to the activation of the coagulation and the complement cascade. In this study, we aimed to establish the impact of the COVID-19 pandemic on patients with new onset of cTMA/aHUS in the Vienna TMA cohort and whether COVID-19 or SARS-CoV-2 vaccinations would pose a greater risk of initial manifestation of cTMA/aHUS.
Methods
We used the Vienna TMA cohort database to examine the prevalence of COVID-19-related and of SARS-CoV-2 vaccination-related aHUS/cTMA during the first 3 years of the COVID-19 pandemic in a large single-centre cohort.
Results
Between March 2020 and May 2023, a total of 7 patients experienced their first aHUS/cTMA episode. No patient experienced a TMA relapse or more than one episode during the follow-up period. Three TMA episodes were attributable to either COVID-19 (n = 1; 33%) or SARS-CoV-2 vaccination (n = 2; 66%), respectively. All 3 patients had systemic signs of TMA, and TMA was confirmed by kidney biopsy in all cases. Among the 7 patients, we recorded five infections that triggered one TMA episode (20%) and 19 vaccinations triggered two TMA episodes (10%; p = 0.52, odds ratio 0.47; 95% CI: 0.04–8.39).
Conclusion
We speculate that both SARS-CoV-2 vaccinations and COVID-19 episodes can represent a triggering factor for aHUS/cTMA episodes in (genetically) vulnerable individuals. However, COVID-19 might have a stronger association and might be a stronger trigger than the SARS-CoV-2 vaccines. The incidence of new aHUS cases did not differ from the pre-pandemic era in a large tertiary care centre cohort.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Nephrology and Dialysis, Department of Medicine III, Medical University of Vienna, Vienna, Austria.
- Department of Pathology, Medical University of Vienna, Vienna, Austria.
- Research Laboratory, Department of Internal Medicine and Haematology, and Research Group for Immunology and Haematology, Semmelweis University - Eötvös Loránd Research Network (Office for Supported Research Groups), Bud…
- Genetics Laboratory, Department of Laboratory Medicine, Medical University of Vienna, Vienna, Austria.
Zitieren
APA
Aigner, C., Gaggl, M., Schmidt, S., Kain, R., Kozakowski, N., Oszwald, A., Prohászka, Z., Sunder-Plassmann, R., Schmidt, A., & Sunder-Plassmann, G. (2024). New-Onset Complement-Mediated Thrombotic Microangiopathy during the COVID-19 Pandemic. Kidney and Blood Pressure Research. https://doi.org/10.1159/000541938
Vancouver
Aigner C, Gaggl M, Schmidt S, Kain R, Kozakowski N, Oszwald A, et al. New-Onset Complement-Mediated Thrombotic Microangiopathy during the COVID-19 Pandemic. Kidney and Blood Pressure Research. 2024. doi:10.1159/000541938
BibTeX
@article{Aigner2024,
author = {Aigner, Christof and Gaggl, Martina and Schmidt, Sophie and Kain, Renate and Kozakowski, Nicolas and Oszwald, André and Prohászka, Zoltán and Sunder-Plassmann, Raute and Schmidt, Alice and Sunder-Plassmann, Gere},
title = {New-Onset Complement-Mediated Thrombotic Microangiopathy during the COVID-19 Pandemic},
journal = {Kidney and Blood Pressure Research},
year = {2024},
doi = {10.1159/000541938}
}
EUVIMED